KidneyIntelX.dkd (Renalytix)
Save to shortlistLast reviewed Oct 31, 2026 against the sources listed on this page · How we review
At a glance
KidneyIntelX.dkd is an FDA-authorized, AI-enabled prognostic test that assesses the risk of progressive kidney-function decline in adults with type 2 diabetes and early-stage chronic kidney disease.
- FDA:
- De Novo DEN200052
- Epic:
- Not on record
- Named users:
- Not on record
- Published study:
- Not on record
Description
KidneyIntelX.dkd is an FDA-authorized, AI-enabled prognostic test that assesses the risk of progressive kidney-function decline in adults with type 2 diabetes and early-stage chronic kidney disease. A machine-learning algorithm (a random-forest model) combines blood-based biomarkers, inherited genetics, and EHR data to stratify patients into low, moderate, or high risk over a five-year horizon, helping clinicians target early treatment. Developed at the Icahn School of Medicine at Mount Sinai and licensed to Renalytix, it received FDA De Novo marketing authorization in June 2023, establishing a new device category for chronic kidney disease progression prognostics.
Quick answers
Answered only from the sourced records on this page. Questions we can't answer from the record are left out. How we review
- Is KidneyIntelX.dkd (Renalytix) FDA cleared?
- The public FDA database has one record that our team matched to KidneyIntelX.dkd (Renalytix). The most recent is De Novo DEN200052 (KidneyIntelX.dkd), decided Jun 2023. Check that the cleared use matches how you plan to use it.FDA record DEN200052
Security & contracting
The maker has not reported these details yet. Ask the vendor directly during evaluation.
- Workflow stage
- Not reported
- Integrations
- Not reported
- Data inputs
- Not reported
- Deployment
- Not reported
- Signs a BAA
- Not reported
- SOC 2 report
- Not reported
- HITRUST
- Not reported
- Evidence type
- Not assessed
Readiness details are self-reported by the maker and are not checked by Clinical Intelligence Foundry. Evidence type describes the kind of study or document the listing links to; it is not a rating or endorsement. Confirm compliance documents with the vendor before purchase.
Who's using this
Organizations named in public announcements or by the developer. Inclusion is not an endorsement.
No public deployments found yet (checked Oct 2026). Using this tool? The maker can claim the listing to add customers.
Get weekly updates for Nephrology
Up to 5 new items a week: new tools, FDA decisions and studies. Newest first, never ranked. Confirm by email, unsubscribe any time.
Sources
This listing links to primary sources. Follow the links below to check details directly with the developer, regulator or publication.
WebsiteFDA database records
- DEN200052 · De Novo · Jun 2023KidneyIntelX.dkd
Matched by our team from the public FDA database; checked Nov 10, 2026.
History (2)Show
Dated events on this listing's public record, newest first.
- Sep 13, 2026
Added to CIFoundry
- Jun 29, 2023
FDA De Novo DEN200052 decision datesource
Developer
Renalytix
Renalytix plc
Evaluating this tool?
Get a printable packet for your committee: what the public record shows, the gaps to raise with the vendor, and the questions for this kind of tool.
Prepare evaluation packetChecklist for your role: Admin · Physician · IT · Compliance
Compare similar tools →